The biotech sector has had a solid third-quarter earnings season, but with stocks nearing four-year highs, analysts at RBC Capital ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE